EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases

Satoshi Yamasaki iD, Takahiko Horiuchi

Hematology Reports · 06.03.2023 · 15 (1) · 180-187

DOI: 10.3390/hematolrep15010019 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hematology Reports, online erschienen am 06.03.2023. Verfasst von Satoshi Yamasaki und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu 874-0840, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, and dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, have been approved for the treatment of renal anemia in Japan, their efficacy and safety for patients aged 80 years or older with low-risk myelodysplastic syndrome (MDS)-related anemia have not been demonstrated. Our case series comprised two men and one woman aged >80 years with low-risk MDS-related anemia and diabetic mellitus (DM)-related chronic kidney disease who were dependent on red blood cell transfusions and in whom erythropoiesis-stimulating agents had been insufficient. All three patients received daprodustat and additional dapagliflozin achieved red blood cell transfusion independence and were followed up for >6 months. Daily oral daprodustat was well tolerated. There were no fatalities or progression to acute myeloid leukemia during the >6-month follow-up after daprodustat initiation. On the basis of these outcomes, we consider 24 mg of daprodustat combined with 10 mg of dapagliflozin daily an effective form of treatment for low-risk MDS-related anemia. Further studies are required to clarify the synergistic effects of daprodustat and dapagliflozin, which correct chronic kidney disease-related anemia by promoting endogenous erythropoietin production and normalizing iron metabolism to manage low-risk MDS in the long term.

Schlagwörter

Stichwörter der Autor:innen

anemiachronic kidney diseasehypoxia-inducible factor-prolyl-hydroxylase inhibitormyelodysplastic syndromesodium-glucose cotransporter 2 inhibitor

Autor:innen und Institutionen

  • Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu 874-0840, Japan.
  • Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka 810-0065, Japan.

ORCID-Profile: Satoshi Yamasaki

Förderung

  • Japan Society for the Promotion of Science
  • JSPS KAKENHI

Zitieren

APA

Yamasaki, S., & Horiuchi, T. (2023). Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases. Hematology Reports, 15(1), 180-187. https://doi.org/10.3390/hematolrep15010019

Vancouver

Yamasaki S, Horiuchi T. Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases. Hematology Reports. 2023;15(1):180-187. doi:10.3390/hematolrep15010019

BibTeX
@article{Yamasaki2023,
  author = {Yamasaki, Satoshi and Horiuchi, Takahiko},
  title = {Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases},
  journal = {Hematology Reports},
  year = {2023},
  volume = {15},
  number = {1},
  pages = {180--187},
  doi = {10.3390/hematolrep15010019}
}
Kostenlos starten →